Bicycle Therapeutics reports Q3 2026 results, orphan drug status for nuzefatide in pancreatic cancer
The FDA designation and planned radioligand trial for BT1702 come as the company reports $469.9 million in cash and a runway into 2030.
SEC filing
1 story
The FDA designation and planned radioligand trial for BT1702 come as the company reports $469.9 million in cash and a runway into 2030.
SEC filing